Biologic targeted therapy in allergic asthma

被引:45
作者
Bice, Jeffrey B. [1 ]
Leechawengwongs, Evelyn [2 ]
Montanaro, Anthony [2 ]
机构
[1] Tulane Univ, Sch Med, New Orleans, LA 70112 USA
[2] Oregon Hlth & Sci Univ, Portland, OR 97201 USA
关键词
NECROSIS-FACTOR-ALPHA; CRTH2 ANTAGONIST OC000459; SOLUBLE IL-4 RECEPTOR; ADD-ON THERAPY; DOUBLE-BLIND; MONOCLONAL-ANTIBODY; AIRWAY INFLAMMATION; MESSENGER-RNA; TNF-ALPHA; PRECLINICAL EFFICACY;
D O I
10.1016/j.anai.2013.12.013
中图分类号
R392 [医学免疫学];
学科分类号
100102 ;
摘要
Objective: To review the structure, function, clinical utility, and safety of current biologic targeted therapies being used for the treatment of asthma. Data Sources: Medical literature obtained from PubMed and OVID searches from June to November 2013. Study Selections: Studies were selected based on article impact, relevance, and clinical significance. Particular emphasis was placed on articles discussing therapies targeted at IgE, interleukin (IL)-4, IL-4 receptor, IL-5, IL-13, tumor necrosis factor-alpha, CRTh2, and toll-like receptors 7 and 9. Results: Since the approval of omalizumab in 2003, the development of biologic asthma therapies has grown at a remarkable pace. With approximately 30 drugs currently in clinical trials and dozens more in development, the future of asthma biologic therapies is promising. Despite several well-publicized setbacks, researchers remain focused on elucidating the complex pathophysiology of asthma. The hope is that asthma biologic therapies will eventually be tailored to an individual's asthma phenotype. With more than 300 million people worldwide affected by asthma and with roughly 5% to 10% of this population living with severe, uncontrolled asthma, the need for new biologic therapies is great. Conclusion: The introduction of each new biologic therapy into clinical trials has been associated with great anticipation, but the outcome of these trials, in many cases, has led to disappointment. Given the lack of overwhelming positive responses, these results have emphasized that asthma is a complex clinical syndrome with multiple underlying genotypes and clinical phenotypes. It has become abundantly clear that it is very unlikely that there is one "magic bullet" to cure all patients with asthma. (C) 2014 American College of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved.
引用
收藏
页码:108 / 115
页数:8
相关论文
共 76 条
[1]   A randomized, double-blind, placebo-controlled study of the CRTH2 antagonist OC000459 in moderate persistent asthma [J].
Barnes, N. ;
Pavord, I. ;
Chuchalin, A. ;
Bell, J. ;
Hunter, M. ;
Lewis, T. ;
Parker, D. ;
Payton, M. ;
Collins, L. Pearce ;
Pettipher, R. ;
Steiner, J. ;
Perkins, C. M. .
CLINICAL AND EXPERIMENTAL ALLERGY, 2012, 42 (01) :38-48
[2]   The novel TLR-9 agonist QbG10 shows clinical efficacy in persistent allergic asthma [J].
Beeh, Kai-Michael ;
Kanniess, Frank ;
Wagner, Frank ;
Schilder, Cordula ;
Naudts, Ingomar ;
Hammann-Haenni, Anya ;
Willers, Joerg ;
Stocker, Hans ;
Mueller, Philipp ;
Bachmann, Martin F. ;
Renner, Wolfgang A. .
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2013, 131 (03) :866-874
[3]   Evidence of a role of tumor necrosis factor α in refractory asthma [J].
Berry, MA ;
Hargadon, B ;
Shelley, M ;
Parker, D ;
Shaw, DE ;
Green, RH ;
Bradding, P ;
Brightling, CE ;
Wardlaw, AJ ;
Pavord, ID .
NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (07) :697-708
[4]   Biological characterization of a novel class of toll-like receptor 7 agonists designed to have reduced systemic activity [J].
Biffen, M. ;
Matsui, H. ;
Edwards, S. ;
Leishman, A. J. ;
Eiho, K. ;
Holness, E. ;
Satterthwaite, G. ;
Doyle, I. ;
Wada, H. ;
Fraser, N. J. ;
Hawkins, S. L. ;
Aoki, M. ;
Tomizawa, H. ;
Benjamin, A. D. ;
Takaku, H. ;
McInally, T. ;
Murray, C. M. .
BRITISH JOURNAL OF PHARMACOLOGY, 2012, 166 (02) :573-586
[5]   Inhibition of human interleukin-13-induced respiratory and oesophageal inflammation by anti-human-interleukin-13 antibody (CAT-354) [J].
Blanchard, C ;
Mishra, A ;
Saito-Akei, H ;
Monk, P ;
Anderson, I ;
Rothenberg, ME .
CLINICAL AND EXPERIMENTAL ALLERGY, 2005, 35 (08) :1096-1103
[6]   Efficacy of soluble IL-4 receptor for the treatment of adults with asthma [J].
Borish, LC ;
Nelson, HS ;
Corren, J ;
Bensch, G ;
Busse, WW ;
Whitmore, JB ;
Agosti, JM .
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2001, 107 (06) :963-970
[7]   Interleukin-4 receptor in moderate atopic asthma - A phase I/II randomized, placebo-controlled trial [J].
Borish, LC ;
Nelson, HS ;
Lanz, MJ ;
Claussen, L ;
Whitmore, JB ;
Agosti, JM ;
Garrison, L .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 1999, 160 (06) :1816-1823
[8]   Safety and efficacy of the prostaglandin D2 receptor antagonist AMG 853 in asthmatic patients [J].
Busse, William W. ;
Wenzel, Sally E. ;
Meltzer, Eli O. ;
Kerwin, Edward M. ;
Liu, Mark C. ;
Zhang, Nan ;
Chon, Yun ;
Budelsky, Alison L. ;
Lin, Joseph ;
Lin, Shao-Lee .
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2013, 131 (02) :339-345
[9]   Safety profile, pharmacokinetics, and biologic activity of MEDI-563, an anti-IL-5 receptor α antibody, in a phase I study of subjects with mild asthma [J].
Busse, William W. ;
Katial, Rohit ;
Gossage, David ;
Sari, Suha ;
Wang, Bing ;
Kolbeck, Roland ;
Coyle, Anthony J. ;
Koike, Masamichi ;
Spitalny, George L. ;
Kiener, Peter A. ;
Geba, Gregory P. ;
Molfino, Nestor A. .
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2010, 125 (06) :1237-1244
[10]   Reslizumab for Poorly Controlled, Eosinophilic Asthma A Randomized, Placebo-controlled Study [J].
Castro, Mario ;
Mathur, Sameer ;
Hargreave, Frederick ;
Boulet, Louis-Philippe ;
Xie, Fang ;
Young, James ;
Wilkins, H. Jeffrey ;
Henkel, Timothy ;
Nair, Parameswaran .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2011, 184 (10) :1125-1132